CYTOKINETICS, INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 281.87 thousand shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2018-03-05
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2017-12-31 was 50.47K shares, a 366.64% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2017-09-30 was 63.10K shares, a 47.44% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2017-06-30 was 24.68K shares, a 60.76% decline year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2017-03-31 was 143.62K shares, a 1.88% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2017 was 281.87K shares, a 9.48% increase from fiscal 2016.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2016 was 257.46K shares, a 21.21% decline from fiscal 2015.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2015 was 326.76K shares, a 240.45% increase from fiscal 2014.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2014 was 95.98K shares, a 18.24% decline from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | 50.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | 113.57K shares derived: sum of 2 quarters · filed 2018-03-05 | 138.25K shares derived: sum of 3 quarters · filed 2018-03-05 | 281.87K shares 10-K · filed 2018-03-05 | |
| 2017-09-30 | 63.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | 87.78K shares derived: sum of 2 quarters · filed 2017-11-03 | 231.39K shares 10-Q · filed 2017-11-03 | 242.21K shares derived: sum of 4 quarters · filed 2017-11-03 | |
| 2017-06-30 | 24.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | 168.29K shares 10-Q · filed 2017-08-04 | 179.11K shares derived: sum of 3 quarters · filed 2017-08-04 | 221.91K shares derived: sum of 4 quarters · filed 2017-08-04 | |
| 2017-03-31 | 143.62K shares 10-Q · filed 2017-05-04 | 154.43K shares derived: sum of 2 quarters · filed 2017-05-04 | 197.23K shares derived: sum of 3 quarters · filed 2017-05-04 | 260.11K shares derived: sum of 4 quarters · filed 2017-05-04 | |
| 2016-12-31 | 10.82K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-06 | 53.61K shares derived: sum of 2 quarters · filed 2017-03-06 | 116.50K shares derived: sum of 3 quarters · filed 2017-03-06 | 257.46K shares 10-K · filed 2017-03-06 | |
| 2016-09-30 | 42.80K shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-12-15 | 105.68K shares derived: sum of 2 quarters · filed 2016-12-15 | 246.65K shares 10-Q/A · filed 2016-12-15 | 426.95K shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2016-06-30 | 62.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | 203.85K shares 10-Q · filed 2016-08-04 | 384.15K shares derived: sum of 3 quarters · filed 2017-03-06 | 426.34K shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2016-03-31 | 140.97K shares 10-Q · filed 2016-05-05 | 321.26K shares derived: sum of 2 quarters · filed 2017-03-06 | 363.46K shares derived: sum of 3 quarters · filed 2017-03-06 | 435.33K shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-12-31 | 180.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | 222.49K shares derived: sum of 2 quarters · filed 2017-03-06 | 294.36K shares derived: sum of 3 quarters · filed 2017-03-06 | 326.76K shares 10-K · filed 2017-03-06 | |
| 2015-09-30 | 42.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 114.06K shares derived: sum of 2 quarters · filed 2015-11-05 | 146.47K shares 10-Q · filed 2015-11-05 | 186.24K shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-06-30 | 71.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | 104.27K shares 10-Q · filed 2015-08-05 | 144.05K shares derived: sum of 3 quarters · filed 2017-03-06 | 164.09K shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-03-31 | 32.40K shares 10-Q · filed 2015-05-04 | 72.18K shares derived: sum of 2 quarters · filed 2017-03-06 | 92.21K shares derived: sum of 3 quarters · filed 2017-03-06 | 96.80K shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2014-12-31 | 39.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | 59.81K shares derived: sum of 2 quarters · filed 2017-03-06 | 64.39K shares derived: sum of 3 quarters · filed 2017-03-06 | 95.98K shares 10-K · filed 2017-03-06 | |
| 2014-09-30 | 20.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | 24.62K shares derived: sum of 2 quarters · filed 2014-11-06 | 56.20K shares 10-Q · filed 2014-11-06 | 105.39K shares derived: sum of 4 quarters · filed 2016-03-03 | |
| 2014-06-30 | 4.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 36.17K shares 10-Q · filed 2014-08-07 | 85.36K shares derived: sum of 3 quarters · filed 2016-03-03 | 116.10K shares derived: sum of 4 quarters · filed 2016-03-03 | |
| 2014-03-31 | 31.59K shares 10-Q · filed 2014-05-07 | 80.78K shares derived: sum of 2 quarters · filed 2016-03-03 | 111.52K shares derived: sum of 3 quarters · filed 2016-03-03 | 20.87K shares derived: sum of 4 quarters · filed 2016-03-03 | |
| 2013-12-31 | 49.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | 79.94K shares derived: sum of 2 quarters · filed 2016-03-03 | -10.72K shares derived: sum of 3 quarters · filed 2016-03-03 | 117.39K shares 10-K · filed 2016-03-03 | |
| 2013-09-30 | 30.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | -59.91K shares derived: sum of 2 quarters · filed 2013-11-06 | 68.20K shares 10-Q · filed 2013-11-06 | -798.54K shares derived: sum of 4 quarters · filed 2015-03-06 | |
| 2013-06-30 | -90.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | 37.46K shares 10-Q · filed 2013-08-07 | -829.29K shares derived: sum of 3 quarters · filed 2015-03-06 | -437.91K shares derived: sum of 4 quarters · filed 2015-03-06 | |
| 2013-03-31 | 128.11K shares 10-Q · filed 2013-05-08 | -738.63K shares derived: sum of 2 quarters · filed 2015-03-06 | -347.26K shares derived: sum of 3 quarters · filed 2015-03-06 | ||
| 2012-12-31 | -866.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-06 | -475.37K shares derived: sum of 2 quarters · filed 2015-03-06 | 210.99K shares 10-K · filed 2015-03-06 | 1.27M shares 10-K · filed 2013-03-15 | |
| 2012-09-30 | 391.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | 1.08M shares 10-Q · filed 2012-11-07 | |||
| 2012-06-30 | 686.36K shares 10-Q · filed 2012-08-06 | ||||
| 2011-12-31 | 173.57K shares 10-K · filed 2014-03-07 | 1.04M shares 10-K · filed 2013-03-15 | |||
| 2010-12-31 | 752.29K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |